Synthesis and in vitro antimycobacterial activity of 3-substituted 5-hydroxy-5-trifluoro[chloro]methyl-4,5-dihydro-1H-1-(isonicotinoyl) pyrazoles

International Journal of Antimicrobial Agents

Volumn 32, Issue 2, 2008, Pages 139-144

  Almeida da Silva, Pedro E ^a   Ramos, Daniela F ^a   Bonacorso, Helio G ^b   de la Iglesia, Agustina I ^c   Oliveira, Marli R ^b   Coelho, Tatiane ^a   Navarini, Jussara ^b   Morbidoni, Hector R ^c   Zanatta, Nilo ^b   Martins, Marcos A P ^b  

^a FEDERAL UNIVERSITY OF RIO GRANDE   (Brazil)

^b FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

^c UNIVERSIDAD NACIONAL DE ROSARIO   (Argentina)

Author keywords

Antimycobacterial activity; Mycobacterium tuberculosis; Pyrazoles; Pyrazolines

Indexed keywords

3 (2 FURYL) 5 HYDROXY 5 TRIFLUOROMETHYL 4,5 DIHYDRO 1H 1 (ISONICOTINOYL)PYRAZOLE; 5 HYDROXY 3 (4 METHYLPHENYL) 5 TRIFLUOROMETHYL 4,5 DIHYDRO 1H 1 (ISONICOTINOYL) PYRAZOLE; 5 HYDROXY 5 TRIFLUOROMETHYL 4,5 DIHYDRO 1H 1 (ISONICOTINOYL) PYRAZOLE; ANTIMYCOBACTERIAL AGENT; ISONIAZID;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENETICS; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL;

ANTITUBERCULAR AGENTS; DRUG RESISTANCE, BACTERIAL; HUMANS; ISONIAZID; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS; PYRAZOLES;

EID: 46049088103     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2008.03.019     Document Type: Article

References (41)

1. World Health Organization. WHO Report. Global tuberculosis control-surveillance, planning, financing. Geneva, Switzerland: WHO; 2007.
2. Raviglione M.C., and Uplekar M.W. WHO's new Stop TB Strategy. Lancet 367 (2006) 952-955
3. World Health Organization. The global MDR-TB & XDR-TB Response Plan, 2007-2008. WHO/HTM/TB/2007.387. Geneva, Switzerland: WHO; 2007.
4. Almeida de Silva P, Aínsa JA. Drugs and drug interactions. In: Palomino JC, Leão SC, Ritacco V, editors. Tuberculosis 2007. From basic science to patient care. http://www.TuberculosisTextbook.com. [accessed 26 March 2008].
5. Guna R., Muñoz C., Dominguez V., et al. In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of Mycobacterium kansasii. J Antimicrob Chemother 55 (2005) 950-953
6. Bernstein J., Lott W.A., Steinberg B.A., and Yale H.L. Chemotherapy of experimental tuberculosis. V. Isonicotinic acid hydrazide (nydrazid) and related compounds. Am Rev Tuberc 65 (1952) 357-364
7. Wang J.Y., Burger R.M., and Drlica K. Role of superoxide in catalase-peroxidase-mediated isoniazid action against mycobacteria. Antimicrob Agents Chemother 42 (1998) 709-711
8. Slayden R.A., Lee R.E., and Barry III C.E. Isoniazid affects multiple components of the type II fatty acid synthase system of Mycobacterium tuberculosis. Mol Microbiol 38 (2000) 514-525
9. Timmns G.S., and Deretic V. Mechanisms of action of isoniazid. Mol Microbiol 62 (2006) 1220-1227
10. Zhang Y., Heym B., Allen B., Young D., and Cole S. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 358 (1992) 591-593
11. Zhang Y., and Telenti A. Genetics of drug resistance in Mycobacterium tuberculosis. In: Hatfull G.F., and Jacobs W.R. (Eds). Molecular genetics of mycobacteria (2000), ASM Press, Washington, DC 235-256
12. Argyrou A., Vetting M.W., Aladegbami B., and Blanchard J.S. Mycobacterium tuberculosis dihydrofolate reductase is a target for isoniazid. Nat Struct Mol Biol 13 (2006) 408-413
13. Takayama K., Wang L., and David H.L. Effect of isoniazid on the in vivo mycolic acid synthesis, cell growth, and viability of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2 (1972) 29-35
14. Banerjee A., Dubnau E., Quemard A., et al. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 263 (1994) 227-230
15. Vilchèze C., Morbidoni H.R., Weisbrod T.R., et al. Inactivation of the inhA-encoded fatty acid synthase II (FASII) enoyl-acyl carrier protein reductase induces accumulation of the FASI end products and cell lysis of Mycobacterium smegmatis. J Bacteriol 182 (2000) 4059-4067
16. Vilchèze C., Wang F., Arai M., et al. Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid. Nat Med 12 (2006) 1027-1029
17. Sreevatsan S., Pan X., Zhang Y., Deretic V., and Musser J.M. Analysis of the oxyR-ahpC region in isoniazid-resistant and -susceptible Mycobacterium tuberculosis complex organisms recovered from diseased humans and animals in diverse localities. Antimicrob Agents Chemother 41 (1997) 600-606
18. Lee A.S., Teo A.S., and Wong S.Y. Novel mutations in ndh in isoniazid-resistant Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother 45 (2001) 2157-2159
19. Ramaswamy S.V., Reich R., Dou S.J., et al. Single nucleotide polymorphisms in genes associated with isoniazid resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 47 (2003) 1241-1250
20. Zhang Y., Post-Martens K., and Denkin S. The magic bullets and tuberculosis drug targets: new drug candidates and therapeutic targets for tuberculosis therapy. Annu Rev Pharmacol Toxicol 45 (2005) 529-564
21. Burman W.J., Gallicano K., and Peloquin C. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet 40 (2001) 327-341
22. Chen P., Gearhart J., Protopopova M., Einck L., and Nacy C.A. Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro. J Antimicrob Chemother 58 (2006) 332-337
23. Falzari K., Zhu Z., Pan D., Liu H., Hongmanee P., and Franzblau S.G. In vitro and in vivo activities of macrolide derivatives against Mycobacterium tuberculosis. Antimicrob Agents Chemother 49 (2005) 1447-1454
24. Jia L., Tomaszewski J.E., Hanrahan C., et al. Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug. Br J Pharmacol 144 (2005) 80-87
25. Moghazeh S.L., Pan X., Arain T., Stover C.K., Musser J.M., and Kreiswirth B.N. Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Antimicrob Agents Chemother 40 (1996) 2655-2657
26. Protopopova M., Hanrahan C., Nikonenko B., et al. Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines. J Antimicrob Chemother 56 (2005) 968-974
27. Cocco M.T., Congiu C., Onnis V., Pusceddu M.C., Shivo M.L., and Logu A. Synthesis and antimycobacterial activity of some isonicotinoylhydrazones. Eur J Med Chem 34 (1999) 1071-1076
28. Costi R., Artico M., Di Santo R., et al. Pyridinylpyrrolyl analogs of isoniazid: synthesis and antimycobacterial activities. Med Chem Res 9 (1999) 408-423
29. Hudson A., Imamura T., Gutteridge W., Kanyok T., and Nunn P. The current anti-TB drug research and development pipeline. UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (2003)
30. 1-nicotinoyl-3-(4′-hydroxy-3′-methyl phenyl)-5-[(sub)phenyl]-2-pyrazolines. Bioorg Med Chem Lett 16 (2006) 3947-3949
31. Maccari R., Ottana R., and Vigorita M.G. In vitro advanced antimycobacterial screening of isoniazid-related hydrazones, hydrazides and cyanoboranes: part 14. Bioorg Med Chem Lett 15 (2005) 2509-2513
32. In: Katritzky A.R., Rees C.W., and Scriven E.F. (Eds). Comprehensive heterocyclic chemistry II 3 (1996), Pergamon Press, Oxford, UK
33. Singh S.P., Kumar D., Batra H., Naithani R., Rozas I., and Elguero J. The reaction between hydrazines and β-dicarbonyl compounds: proposal for a mechanism. Can J Chem 78 (2000) 1109-1120
34. Bonacorso H.G., Martins M.A.P., Bittencourt S.R.T., Lourega R.V., Zanatta N., and Flores F.C. Trifluoroacetylation of unsymmetrical ketone acetals. A convenient route to obtain alkyl side chain trifluormethylated heterocycles. J Fluor Chem 99 (1999) 177
35. Bonacorso H.G., Oliveira M.R., Costa M.B., et al. Regiospecific one-pot synthesis of new trifluoromethyl substituted heteroaryl pyrazolyl ketones. J Heterocycl Chem 42 (2005) 631
36. Bonacorso H.G., Oliveira M.R., Costa M.B., et al. Regiospecific synthesis of new non-condensed heteropolycyclic systems from β-heteroaryl-beta-methoxyvinyl trihalomethyl ketones. J Braz Chem Soc 16 (2005) 868
37. Bonacorso H.G., Oliveira M.R., Costa R.L., et al. One-pot synthesis of aryl and heteroaryl substituted hydroxypyrazolines from the reactions of β-alkoxyvinyl trichloromethyl ketones with heteroarylhydrazines. Heteroatom Chem 17 (2006) 685-691
38. Martins M.A.P., Siqueira G.M., Flores A.F.C., Clar G., and Zanatta N. Síntese de 1,1,1-trialo-4-metóxi-3-buten-2-onas: acilação de cetais. Chem Abstr 122 (1995) 187063a
39. Palomino J., Martin A., Camacho M., Guerra H., Swings J., and Portaels F. Resazurin microtiter assay plate: simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 46 (2002) 2720-2722
40. Morbidoni H.R., Vilchèze C., Kremer L., Bittman R., Sacchettini J.C., and Jacobs Jr. W.R. Dual inhibition of mycobacterial fatty acid biosynthesis and degradation by 2-alkynoic acids. Chem Biol 13 (2006) 297-307
41. Vilchèze C., and Jacobs Jr. W.R. The mechanism of isoniazid killing: clarity through the scope of genetics. Annu Rev Microbiol 61 (2007) 35-50